Clinical trials: Hepatitis
Hepatitis C, Chronic
ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)
This is a Phase 4, retrospective and observational, multicenter, national (Brazil), open, noncomparative, and nonrandomized study, which does not have visits. This study will be conducted in accordance to Good Clinical Practices.
- Trial name
- ATHENAS (NCT00856024)
- Testing
- Peginterferon alfa-2b, Ribavirin
- Volunteers
- 902 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)
The objective of this study is to evaluate the efficacy of three regimens of pegylated interferon-alfa 2b (PEG-IFN) either as monotherapy or in combination with ribavirin in participants with acute hepatitis C.
- Trial name
- NCT00686517
- Testing
- Pegylated interferon alfa-2b, Ribavirin
- Volunteers
- 130 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C
This study will examine the effectiveness of S-adenosyl methionine (SAMe) in combination with peginterferon and ribavirin for treating hepatitis C virus.
- Trial name
- NCT00475176
- Testing
- Peginterferon alfa-2a, Ribavirin, S-adenosyl methionine for Chronic Liver Disease
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis B, Chronic
An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants
The purpose of this study is to evaluate efficacy of the study intervention, based on hepatitis B surface antigen (HBsAg) levels at follow-up (FU) Week 24.
- Trial name
- OCTOPUS-1 (NCT05275023)
- Testing
- JNJ-73763989, PD-1 inhibitor, Tenofovir Disoproxil
- Where
- 26 sites in Canada, Czechia and 6 more
- Volunteers
- 37 people
- Sponsor
- Janssen Research & Development, LLC
Hepatitis D
Lonafarnib for Chronic Hepatitis D
Background: Chronic hepatitis D is a severe disease of the liver caused by infection with the hepatitis D virus. The hepatitis D virus can only infect a person who also has hepatitis B; therefore, people with delta hepatitis have…
- Trial name
- NCT01495585
- Testing
- Lonafarnib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis C, Chronic
A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials
This open-label, non-randomized, single arm study will provide treatment or re-treatment with Pegasys (peginterferon alfa-2a) as monotherapy or in combination with Copegus (ribavirin) to patients with chronic hepatitis C…
- Trial name
- NCT01853254
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 67 sites in United States, Australia and 9 more
- Volunteers
- 272 people
- Sponsor
- Hoffmann-La Roche
Poliomyelitis, Acellular Pertussis
Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children
The new formulation administered as a 4th consecutive dose will be compared to the current formulation of the vaccine in this partially double blind study.
- Conditions
- Poliomyelitis, Acellular Pertussis, Tetanus, Diphtheria
- Trial name
- NCT00611559
- Testing
- Infanrix™ penta, Infanrix™ hexa
- Where
- 3 sites in Russia
- Volunteers
- 283 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C, Hepatitis C, Chronic
Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)
The objective of this study is to determine the relapse rate in the French patient population with chronic hepatitis C (CHC) previously treated with PegInterferon Alfa-2b (Peg-IFN alfa-2b) plus Ribavirin according to standard…
- Trial name
- RE-CHUT (NCT00725842)
- Testing
- Peg-IFN alfa-2b, Ribavirin
- Volunteers
- 97 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + velpatasvir (VEL; GS-5816) with or without ribavirin (RBV) in treatment-naive adults with chronic…
- Trial name
- NCT01858766
- Testing
- SOF, VEL, RBV
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 379 people
- Sponsor
- Gilead Sciences
Hepatitis B
Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone
This study is being conducted to compare the safety and effectiveness of the investigational medication LdT (telbivudine) used in combination with adefovir dipivoxil (a drug currently approved by the Food and Drug Administration…
- Trial name
- NCT00376259
- Testing
- telbivudine, adefovir dipivoxil
- Where
- 6 sites in United States, Hong Kong and 3 more
- Volunteers
- 43 people
- Sponsor
- Novartis
Diphtheria, Tetanus
Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants
The purpose of this trial is to clinically confirm that the manufacturing process of the final bulk products of the investigational DTaP-IPV-HB-PRP~T vaccine is consistent.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00404651
- Testing
- DTaP-IPV-HB-PRP~T vaccine, DTaP-HBV-IPV vaccine
- Where
- 6 sites in Mexico
- Volunteers
- 1,189 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatitis B
Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)
The purpose of this trial is to determine if there is an improvement in the immune response of older adults over 50 years of age using a modified process hepatitis B vaccine and a currently licensed hepatitis B vaccine…
- Trial name
- NCT00440531
- Testing
- Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), Comparator: Modified Process Hepatitis B Vaccine (Experimental), Comparator: ENGERIX-B™ (currently licensed product)
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)
This study is being done to evaluate the efficacy and safety of the drug combination grazoprevir (GZR; MK-5172) + elbasvir (EBR; MK-8742) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infection and…
- Trial name
- NCT02115321
- Testing
- Grazoprevir, Elbasvir, MK-5172A
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic, Hepacivirus
Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)
Study P05063 is a 3-year long-term follow-up (LTFU) study in participants previously treated with boceprevir (BOC) or narlaprevir (NAR) in a Phase 1, 2, or 3 clinical study.
- Trial name
- NCT00689390
- Testing
- Boceprevir, Narlaprevir, Peginterferon alfa-2b
- Volunteers
- 1,954 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Liver Transplantation
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C
This study will assess the rates of Sustained Virological Response following anti-viral therapy with Peg-Interferon plus Ribavirin in patients that have been liver transplanted with recurrent Hepatitis C and treated with Neoral…
- Trial name
- SUSTAIN (NCT00938860)
- Testing
- cyclosporin (Neoral), tacrolimus (Prograf)
- Where
- 45 sites in United States, Belgium and 11 more
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C Virus
A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
To demonstrate the effectiveness of Daclatasvir (DCV) 3 Direct Acting Antivirals (DAA) fixed dose combination in Genotype 1 Chronic Hepatitis C subjects.
- Trial name
- UNITY 4 (NCT02170727)
- Testing
- DCV/ASV/BMS-791325
- Where
- 20 sites in Russia, South Korea and 1 more
- Volunteers
- 199 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Genotype 1
Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus
The purpose of this open label study is to evaluate the safety and efficacy of daclatasvir plus pegylated interferon-alfa 2a and ribavirin in untreated hepatitis C virus in patients coinfected with HIV
- Trial name
- NCT01471574
- Testing
- Daclatasvir, Ribavirin, PEG-Interferon alfa 2a
- Where
- 86 sites in United States, Argentina and 11 more
- Volunteers
- 549 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C Virus (HCV Infection Genotype 1)
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults
This open-label study will evaluate the safety and efficacy of co-formulated ombitasvir/paritaprevir/ritonavir and dasabuvir co-administered with sofosbuvir with or without ribavirin administered for either 4 or 6 weeks in…
- Trial name
- NCT02399345
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir, sofosbuvir (SOF), ribavirin (RBV)
- Volunteers
- 10 people
- Sponsor
- AbbVie
Hepatitis C Infection, HIV Infection
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
The purpose of this study was to assess the efficacy of a fixed dose combination (FDC) of glecaprevir/pibrentasvir (G/P) given for 4 weeks for treatment of acute hepatitis C (HCV), with or without HIV-1 coinfection.
- Trial name
- PURGE-C (NCT04042740)
- Testing
- Glecaprevir/Pibrentasvir (G/P)
- Where
- 12 sites in United States, Brazil
- Volunteers
- 45 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Carcinoma, Hepatocellular, Chronic Hepatitis B
The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC)
The purpose of this study is to evaluate the effect of serum hepatitis B virus (HBV) DNA level on intrahepatic recurrence in locally treatable hepatocellular carcinomas (HCCs) related with HBV.
- Trial name
- NCT00397540
- Testing
- PEIT, RFTA
- Where
- South Korea
- Volunteers
- 145 people
- Sponsor
- Seoul National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.